Panel: Cancer Therapy Patent Lacks Written Description Support

Mealey's (August 31, 2021, 1:39 PM EDT) -- WASHINGTON, D.C. — An award of $1.2 billion in damages for infringement of a cancer immunotherapy patent was reversed Aug. 26 by the Federal Circuit U.S. Court of Appeals, based upon the panel’s finding that the patent in suit suffers from inadequate written description support....